neuroinfuse™ drug delivery system
Novel chronic and acute catheter systems for direct delivery of therapeutics to the brain
Crossing the blood-brain barrier
Intraparenchymal drug delivery offers a practical method of bypassing the blood-brain barrier (BBB) and shows great promise in providing the next step change in the treatment of neurodegenerative, neuro oncology and other debilitating neurological conditions.
We are developing a patented range of engineering solutions to cover chronic (long term) implantable and acute (short term) implantable intraparenchymal drug delivery. Our low dead volume chronic device has a novel, MRI compatible, transcutaneous port that aims to provide a solution for simultaneous intermittent drug delivery to the central nervous system (CNS) through multiple catheters (up to four) at any time interval.
A complete robotic platform
Features and benefits
|Implantation performed outside of MRI||Reduces the burden on costly MRI equipment and radiologists|
|MRI compatible||Enables real-time imaging of infusions|
|Acute infusions||Suitable for one-off infusions, catheter can be explanted after use|
|Chronic infusions||Enables repeated infusions and flexible administration regimes|
|Patient specific||Catheter length can be adjusted to encourage custom therapy distribution|
|4-channel re-accessible catheter system with independent fluid paths and flow rates||Allows the clinician to control and customise the therapy|
|Repeat administrations do not require additional surgery||Reduces inherent risk of repeated surgery|
|Repeated delivery of fixed volumes||Aims to deliver consistent and repeatable treatment|
|Outpatient infusions||Reduces strain on in-patient facilities|
Working with clinical partners
Over several years Renishaw has been working with experienced clinical experts to produce a specification for an intraparenchymal drug delivery device and stereotactic delivery platform that facilitates convection enhanced delivery (CED) and other infusion applications.
The chronic product is currently undergoing clinical investigation as part of the Horizon 2020 funded TreatER project. TreatER is a first-in-human clinical study examining the intraparenchymal delivery of CDNF for the treatment of Parkinson's disease.
Drug development opportunities
The development team behind the neuroinfuse drug delivery system has considerable experience investigating CED. By using our products and engaging with our engineers as early as possible, pharmaceutical partners can help ensure new therapies suitable for intraparenchymal delivery are translated into clinical practice as smoothly as possible. Testing the drug and delivery method in combination enables product trouble-shooting to take place well in advance of clinical investigation. As uncertainty is addressed and risk reduced at each development stage, this collaborative approach provides investors and pharmacological experts with the confidence required to move in to subsequent translational stages.
At present, the Renishaw neuroinfuse drug delivery system can only be used in the setting of an approved clinical trial. Renishaw is currently seeking academic, clinical and commercial partners across a wide range of indications, from oncology to neurodegenerative diseases. The purpose of this website is only to obtain partners and not to make the device generally available.